Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA approves Aurobindo's OTC cetirizine liquid

This article was originally published in The Tan Sheet

Executive Summary

The agency approves Aurobindo Pharma Limited's cetirizine hydrochloride solution, which the Hyderabad, India-based firm plans to launch "shortly." The product is the generic equivalent of McNeil Consumer Healthcare's Children's Zyrtec Allergy and Children's Zyrtec Hives Relief, both oral solutions containing cetirizine HCl and packaged in 1 mg/mL bottles. It will join the growing number of products in the category, which for the 52 weeks ended Jan. 24 had sales of $630.9 million, according to data from Information Resources, Inc. a Chicago-based market research firm. Private-label products in the category sold $149.3 million in the same period, while Johnson & Johnson/McNeil's liquid and powder Zyrtec products sold $26.4 million and Schering-Plough's Claritin liquid/powder products sold $12.7 million

You may also be interested in...

Sales Already Growing As Vascepa Secures Cardio Approval

UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.

Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance

Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts